Renée Aguiar-Lucander, CEO of Calliditas, is driving the advancement and launch of TARPEYO – the company’s medication targeting rare disease IgA nephropathy. We spoke with Renée about her journey from investment banking to science and the joy of bringing therapies to patients.
Bristol Myers Squibb partners with Repertoire Immune Medicines to develop innovative vaccines aimed at treating autoimmune disorders more selectively and effectively
With equipment that promises to produce 10 times more therapies, the deal with Cellares is hoped to make BSM's CAR-T ambitions more scalable and affordable